Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 21;12(9):2703. doi: 10.3390/cancers12092703

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Response to sunitinib in a patient affected by intraperitoneal metastases from an extraskeletal myxoid chondrosarcoma (EMC) primary of the thigh. (A) Hematoxylin and eosin stain of extraskeletal myxoid chondrosarcoma arising from the thigh; (B) Fluorescence in situ hybridization FISH analysis confirming NR4A3 rearrangement (split signals: centromere, orange; telomere, green, in contrast to normal fused signals); (C) Peritoneal metastases (red circles) treated with sunitinib 37.5 mg/day with complete response (green arrow; no more tumor lesion detectable in (D) maintained over 2 years. After two years of treatment, sunitinib was discontinued with evidence of progression (red arrow) after 8 months from discontinuation, as confirmed by the appearance of a new peritoneal lesion ((E), red circle). A new complete response was achieved after rechallenging sunitinib (green arrow, no tumor lesion in (F)).

Response to sunitinib in a patient affected by intraperitoneal metastases from an extraskeletal myxoid chondrosarcoma (EMC) primary of the thigh. (A) Hematoxylin and eosin stain of extraskeletal myxoid chondrosarcoma arising from the thigh; (B) Fluorescence in situ hybridization FISH analysis confirming NR4A3 rearrangement (split signals: centromere, orange; telomere, green, in contrast to normal fused signals); (C) Peritoneal metastases (red circles) treated with sunitinib 37.5 mg/day with complete response (green arrow; no more tumor lesion detectable in (D) maintained over 2 years. After two years of treatment, sunitinib was discontinued with evidence of progression (red arrow) after 8 months from discontinuation, as confirmed by the appearance of a new peritoneal lesion ((E), red circle). A new complete response was achieved after rechallenging sunitinib (green arrow, no tumor lesion in (F)).